GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Shiller PE Ratio

SGMO (Sangamo Therapeutics) Shiller PE Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sangamo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Sangamo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Shiller PE Ratio Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sangamo Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sangamo Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Sangamo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Shiller PE Ratio falls into.



Sangamo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sangamo Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Sangamo Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.04/133.0289*133.0289
=0.040

Current CPI (Sep. 2024) = 133.0289.

Sangamo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.060 99.070 -0.081
201503 -0.080 99.621 -0.107
201506 -0.170 100.684 -0.225
201509 -0.130 100.392 -0.172
201512 -0.200 99.792 -0.267
201603 -0.230 100.470 -0.305
201606 -0.380 101.688 -0.497
201609 -0.270 101.861 -0.353
201612 -0.140 101.863 -0.183
201703 -0.230 102.862 -0.297
201706 -0.170 103.349 -0.219
201709 -0.150 104.136 -0.192
201712 -0.150 104.011 -0.192
201803 -0.230 105.290 -0.291
201806 -0.170 106.317 -0.213
201809 -0.130 106.507 -0.162
201812 -0.180 105.998 -0.226
201903 -0.410 107.251 -0.509
201906 -0.260 108.070 -0.320
201909 -0.240 108.329 -0.295
201912 0.040 108.420 0.049
202003 -0.370 108.902 -0.452
202006 -0.260 108.767 -0.318
202009 -0.010 109.815 -0.012
202012 -0.290 109.897 -0.351
202103 -0.320 111.754 -0.381
202106 -0.330 114.631 -0.383
202109 -0.330 115.734 -0.379
202112 -0.260 117.630 -0.294
202203 -0.300 121.301 -0.329
202206 -0.290 125.017 -0.309
202209 -0.340 125.227 -0.361
202212 -0.320 125.222 -0.340
202303 0.120 127.348 0.125
202306 -0.660 128.729 -0.682
202309 -0.590 129.860 -0.604
202312 -0.340 129.419 -0.349
202403 -0.270 131.776 -0.273
202406 -0.180 132.554 -0.181
202409 0.040 133.029 0.040

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sangamo Therapeutics  (NAS:SGMO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sangamo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics Business Description

Traded in Other Exchanges
Address
501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005